Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ182MR)

This product GTTS-WQ182MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC), Coat's disease research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ182MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2085MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ7654MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ7320MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ6241MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CR57
GTTS-WQ15928MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ6288MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ8683MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ12948MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW